Содержание материала


  1. Clinical Guidelines Task Force, International Diabetes Federation. Global Guideline for Type 2 Diabetes, 2005 (www.idf.org; last accessed 30 April 2008).
  2. Confidential Enquiry into Maternal and Child Health. Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland. СЕМАСН: London, 2007.
  3. Hawthorne G, Robson S, Ryall EA, et al. Prospective population based survey of outcome of pregnancy in diabetic women: results of the Northern Diabetic Pregnancy Audit, 1994. BMJ 1997; 315: 279-281.
  4. Jensen DM, Damm P, Moelsted-Pederson L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004; 27: 2819-2823.
  5. Penney GC, Mair G, Pearson DWM, et al. Outcomes of pregnancies in women with type 1 diabetes in Scotland: a national population-based study. Br J Obstet Gynaecol 2003; 110: 315-318.
  6. Evers IM, de Valk HW, Visser GHA. Risk of complications or pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328: 915-918.
  7. Casson IF, Clarke CA, Howard CV, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315: 275-278.
  8. Yang J, Cummings EA, O'Connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol 2006; 108: 644-650.
  9. Macintosh MCM, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006; 333: 177-180.
  10. Diabetes and Pregnancy Group, France. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003; 26:2990-2993.
  11. Piatt MJ, Stanisstreet M, Casson IF, et al. St Vincent's declaration 10 years on: outcomes of diabetic pregnancies. Diabet Med 2002; 19: 216-220.
  12. Confidential Enquiry into Maternal and Child Health. Pregnancy in Women with Type 1 and Type 2 Diabetes, 2003-2003, England, Wales and Northern Ireland. СЕМАСН: London, 2005.
  13. Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med 2005; 10:333-339.
  14. Clausen TD, Mathiesen ER, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-328.
  15. Leinonen PJ, Hiilesmaa VK, Kaaja RJ, Teramo KA. Maternal mortality in type 1 diabetes. Diabetes Care 2001; 24:1501-1502.
  16. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004; 27 (Suppl 1): S88-S90.
  17. Department of Health. National Service Framework for Diabetes: Standards. London: Department of Health, 2001.
  18. Crowther CA, Hilier JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New Engl J Med 2005; 352: 2477-2486.
  19. O'Sullivan J. The Boston gestational diabetes studies. In: HW Sutherland, JM Stowers and DWM Pearson, eds. Carbohydrate Metabolism in Pregnancy and the Newborn. London: Springer-Verlag; 1989:287-294.
  20. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Geneva: World Health Oraanization. 1999. nancies in women with type 1 diabetes. Diabetes Care 2006; 29: 2612-2616.
  21. Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mel- litus: systematic review of observational studies. BMC Pregnancy and Childbirth 2006; 6: 30: doi:10.1186/1471-2393-6-30.
  22. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
  23. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformatio rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988; 318: 671-676.
  24. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care 2007; 30:467-470.
  25. HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet 2002; 78:69-77.
  26. Hampton T. Study finds newborn outcomes affected by blood glucose levels during pregnancy. JAMA 2007; 298:613-614.
  27. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA 1991; 265: 731 -736.
  28. Gunderson EP. Gestational diabetes and nutritional recommendations. Curr Diab Rep 2004; 4: 377-386.
  29. Jovanovic-Peterson L, Peterson CM. Exercise and the nutritional management of diabetes during pregnancy. Obstet Gynecol Clin North Am 1996; 23:75-86.
  30. Turok DK, Ratcliffe SD, Baxley EG. Management of gestational diabetes mellitus. Am Fam Physician 2003; 68:1767-1772.
  31. Langer O, Anyaegbunam A, Brustman L, et al. Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy. Am J Obstet Gynecol 1989; 161:593-599.
  32. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25: 959-973.
  33. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989; 161:415-419.
  34. Bung P, Artal R, Khodiguian N, Kjos S. Exercise in gestational diabetes: an optional therapeutic approach? Diabetes 1991; 40 (Suppl 2): 182-185.
  35. Brankston GN, Mitchell BF, Ryan EA, Okun NB. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am J Obstet Gynecol 2004; 190:188-193.
  36. Ramsay JE, Ferrell WR, Crawford L, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab 2002; 87: 4231-4237.
  37. Harris GD, White RD. Diabetes management and exercise in pregnant patients with diabetes. Clin Diab 2005; 23: 165-168.
  38. Wolfe LA, Heenan AP, Bonen A. Aerobic conditioning effects on substrate responses during graded cycling in pregnancy. Can J Physiol Pharmacol 2003; 81: 696-703.
  39. Clapp JF 3rd, Kiess W. Effects of pregnancy and exercise on concentrations of the metabolic markers tumor necrosis factor alpha and leptin. Am J Obstet Gynecol 2000; 182: 300-306.
  40. Joint Formulary Committee. British National Formulary (ed 55). British Medical Association and Royal Pharmaceutical Society of Great Britain: London, March 2008.
  41. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-1138.
  42. Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med 2007; 24: 253-258.
  43. Hellmuth E, Damm P, Moisted- Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507-511.
  44. Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
  45. Homko CJ, Sivan E, Reece AE. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? Treat Endocrinol 2004; 3: 133-139.
  46. Kerssen A, de Valk HW, Visser GHA. Do HbA1 с levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus? Diabetologia 2006; 49: 25-28.
  47. Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diab 2004; 22: 169-172.
  48. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-885.
  49. De Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requirung insulin therapy. N Engl J Med 1995; 333: 1237-1241.
  50. Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003; 189: 507-512.
  51. El-Halwagy HE, Gelbaya ТА, El-wahab MF, et al. The mean third trimester postprandial blood glucose of diabetic pregnant patients and infant birth weight in the Kuwaiti population. Medscape General Medicine 2001; 3(4).
  52. Ben-Haroush A, Yogev Y, Chen R, et al. The postprandial glucose profile in the diabetic pregnancy. Am J Obstet Gynecol 2004; 191: 576-581.
  53. Lawson PM, Champion MC, Canny C, et al. Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and pre- proliferative retinopathy. Br J Ophthalmol 1982; 96: 762-766.
  54. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984; 311: 365-372.
  55. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
  56. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631-637.
  57. Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type 1 diabetic women. Diabetes Care 1992; 15: 1034-1037.
  58. Rosenn BM, Miodovnik M, Holcberg G, et al. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstet Gynecol 1995; 85:417-422.
  59. Evers IM, ter Braak EWMT, de Valk HW, et al. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 2002; 25: 554-559.
  60. Buchanan ТА, Schemmer JK, Freinkel N. Embryotoxic effects of brief maternal insulin-hypoglycemia during organogenesis in the rat. J Clin Invest 1986; 78: 643-649.
  61. Smoak IW, Sadler TW. Embryopathy effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol 1990; 163: 619-624.
  62. Hanson U, Persson B. Epidemiology of pregnancy-induced hypertension and preeclampsia in type 1 (insulin-dependent) diabetic pregnancies in Sweden. Acta Obstet Gynecol Scand 1998; 77:620-624.
  63. Siddiqi T, Rosenn B, Mimouni F, et al. Hypertension during pregnancy in insulin-dependent diabetic women. Obstet Gynecol 1991; 77: 514-519.
  64. Leguizamon GF, Zeff NP, Fernandez A. Hypertension and the pregnancy complicated by diabetes. Curr Diab Rep 2006; 6: 297-304.
  65. Sierra-Laguado J, Garcia RG, Celedon J, et al. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancyinduced hypertension. Am J Hypertens 2007; 20: 437-442.
  66. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003; 88: 2393-2398.
  67. Bartha JL, Romero-Carmona R, Torrejon-Cardoso R, Comino-Delgado R. Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension. Am J Obstet Gynecol 2002; 187: 735-740.
  68. Solomon CG, Seely EW. Hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001; 37: 232-239.
  69. Ferriss JB. The causes of raised blood pressure in insulin-dependent and noninsulin-dependent diabetes. J Hum Hypertens. 1991; 5: 245-254.
  70. Jensen T, Deckert T. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulindependent diabetic patients. Horm Metab Res Suppl 1992; 26: 68-70.
  71. Aoki TT, Grecu EO, Gollapudi GM, et al. Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus. Endocr Pract 1999; 5: 174-178.
  72. Mulec H, Blohme G, Grande B, Bjorck S. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 651-655.
  73. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-depend-
  74. Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic woman with microalbuminuria. Diabetes Care 2001; 24:1739- 1744.
  75. Nielsen LR, Muller C, Damm P, Mathiesen ER. Reduced prevalence of preterm delivery in women with type 1 diabetes and microalbuminuria - possible effect of early antihypertensive treatment during pregnancy. Diabet Med 2006; 23: 426-431.
  76. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16(Suppl 3):155-165.
  77. The MJ. Human insulin: DNA technology's first drug. Am J Hosp Pharm 1989; 46(Suppl 2): S9-S11.
  78. Deckert T. The immunogenicity of new insulins. Diabetes 1985; 34(Suppl 2):94-96.
  79. Chertow BS, Baranetsky NG, Sivitz Wl, et al. The effects of human insulin on antibody formation in pregnant diabetics and their newborns. Obstet Gynecol 1988; 72: 724-728.
  80. Nachum Z, Ben-Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319: 1223-1227.
  81. Roy B, Chou MCY, Field JB. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-479.
  82. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
  83. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed ana-logue of human insulin. Diabetes 1994; 43: 396-402.
  84. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin. Diabetes Care 1999; 22: 1501- 1506.
  85. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
  86. Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab Res Rev 2005; 21: 241-252.
  87. Rosskamp RH, Park G. Long-acting insulin analogues. Diabetes Care 1999; 22(Suppl 2): B109-B113.
  88. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7:73-82.
  89. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
  90. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
  91. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23:639-643.
  92. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J 0bes2004; 28(Suppl 2):S23-S28.
  93. Jovanovic L, llic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22:1422-1427.
  94. Bhattacharyya S, Brown S, Hughes S, Vice PA. Insulin lispro and regular human insulin in pregnancy. Q J Med 2001; 94: 255-260.
  95. Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 115-121.
  96. Diamond TD, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009-1010.
  97. Kitzmiller JL, Main E, Ward B, et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22:874-875.
  98. Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes traeted with insulin lispro during pregnancy. Diabet Med 2005; 22: 803-807.
  99. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776.
  100. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198: 186.e1-7.
  101. Pettit DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003; 26: 183-186.
  102. Klein O, Lynge J, Endahl L, et al. Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 2006; 55(Suppl 1):A76.
  103. Heise T, Nosek L, Biilmann Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614-1620.
  104. Woolderink JM, van Loon AJ, Storms F, et al. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 2005; 28:2594-2595.
  105. Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 2002; 25: 1095-1096.
  106. Di Cianni G, Volpe L, Lencioni C, et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 2005; 28:982-983.
  107. Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007; 114:453-457.
  108. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
  109. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
  110. Roach P, Yue L, Arora V, The Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
  111. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19:393-399.
  112. Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001; 24:1130-1136.
  113. Langer O, Anyaegbunam A, Brustman L, et al. Progestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol 1988; 159: 616-621.
  114. Rayburn W, Piehl E, Lewis E, et al. Changes in insulin therapy during pregnancy. Am J Perinatal 1985; 2: 271-275.
  115. Steel JM, Johnstone FD, Hume R, Mao JH. Insulin requirements during pregnancy in women with type 1 diabetes. Obstet Gynecol 1994; 83: 253- 258.
  116. McManus RM, Ryan EA. Insulin requirements in insulin-dependent and insulin-requiring GDM women during final month of pregnancy. Diabetes Care 1992; 15: 1323-1327.
  117. Potter JM, Reckless JPD, Cullen DR. Subcutaneous continuous insulin infusion and control of blood glucose concentration in diabetics in third trimester of pregnancy. Br Med J 1980; 280: 1099-1101.
  118. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabete Metab 1986; 12:121-129.
  119. Gimenez M, Conget I, Nicolau J, et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A casecontrol study. Acta Diabetol 2007; 44:34-37.
  120. Jovanovic L. Glucose and insulin requirements during labor and delivery: the case for normoglycemia in pregnancies complicated by diabetes. Endocr Pract 2004; 10(Suppl 2): 40-45.
  121. Jovanovic L, Peterson CM. Insulin and glucose requirements during the first stage of labor in insulin-dependent diabetic women. Am J Med 1983; 75:607-612.
  122. Njenga E, Lind T, Taylor R. Five year audit of peripartum blood glucose control in type 1 diabetic patients. Diabet Med 1992; 9: 567-570.
  123. Lean MEJ, Pearson DWM, Sutherland HW. Insulin management during labor and delivery in mothers with diabetes. Diabet Med 1990; 7: 162- 164.
  124. Caplan RH, Pagliara AS, Beguin EA, et al. Constant intravenous insulin infusion during labor and delivery in diabetes mellitus. Diabetes Care 1982; 5:6-10.
  125. Rosenberg VA, Eglinton GS, Rauch ER, et al. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195:1095-1099.
  126. Feldberg D, Dicker D, Samuel N, et al. Intrapartum management of insulindependent diabetes mellitus (IDDM) gestants: a comparative study of
  127. Macintosh МСМ, Fleming KM at al. BMJ 2006; 333: 177-180
  128. Hawthorne G et al. BMJ 1997; 315: 279-281
  129. EversIMetal.BMJ 2004; 328: 915
  130. Jensen DM, Damm P et al. Diabetes Care 2004; 27:2819-2823